MEDI-493 data

MEDI released results of its double-blind, placebo-controlled, dose-escalating, multi-center Phase I/II trial of MEDI-493 to prevent RSV disease in

Read the full 196 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE